Personal Profile
Patrick Kiser
Associate Professor
Ph.D., Duke University, Materials Science
M.S. Chemistry; University of Wisconsin-Milwaukee
B.S. University of Wisconsin-Madison
E-mail:
Phone: 801.585.8546
Lab 801.587.8574
Office: 108G BPRB
Lab 801.587.8574
Office: 108G BPRB
Research
Bioactive Polymer Systems, HIV Prevention Science, Women's Health
Current Research
Well into its third decade, the global HIV/AIDS epidemic continues to proliferate within communities that do not routinely practice safe sex. The need to quell the global pandemic has prompted a twenty year global effort to develop pre-exposure prophylaxis (PrEP) technologies that women and men can use to prevent sexual transmission of HIV. The technologies are designed to interfere with one or more steps of the lifecycle of any sexually transmitted infection, and in particular HIV. Our lab applies controlled and triggered drug release principle to the design of antiviral drug delivery systems. Building upon my background, we now have a large number of methodologies and collaborators we can draw on to study and attack these problems, which range from basic virology, materials design and synthesis, to development of new drug delivery systems for early first in humans studies.
We are currently working on projects that range from new materials discovery that could lead to new advanced reproductive health technologies, to the development of new assays and technology to evaluate PrEP modalities, to sustained delivery system projects for both antiviral and contraceptive agents. Several of these projects are developed enough to begin pushing toward the clinic with the help of our collaborators and colleagues at the non-profit Contraceptive Research and Development Organization (CONRAD), The Population Council, Imquest Pharmaceuticals, Albert Einstein University and at the Centers for Disease Control.
We are currently working on projects that range from new materials discovery that could lead to new advanced reproductive health technologies, to the development of new assays and technology to evaluate PrEP modalities, to sustained delivery system projects for both antiviral and contraceptive agents. Several of these projects are developed enough to begin pushing toward the clinic with the help of our collaborators and colleagues at the non-profit Contraceptive Research and Development Organization (CONRAD), The Population Council, Imquest Pharmaceuticals, Albert Einstein University and at the Centers for Disease Control.
Selected Publications
Johnson TJ, Clark MR, Albright TH, Nebeker JS, Tuitupou AL, Clark JT, Fabian J, McCabe RT, Chandra N, Doncel GF, Friend DR, Kiser PF, A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother 2012 Dec;56(12):6272-83
Kiser PF, Mesquita PM, Herold BC, A perspective on progress and gaps in HIV prevention science. AIDS Res Hum Retroviruses 2012 Nov;28(11):1373-8
Clark JT, Johnson TJ, Clark MR, Nebeker JS, Fabian J, Tuitupou AL, Ponnapalli S, Smith EM, Friend DR, Kiser PF, Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J Control Release 2012 Oct 28;163(2):240-8
Kiser PF, Mahalingam A, Fabian J, Smith E, Damian FR, Peters JJ, Katz DF, Elgendy H, Clark MR, Friend DR, Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci 2012 May;101(5):1852-64
Johnson TJ, Srinivasan P, Albright TH, Watson-Buckheit K, Rabe L, Martin A, Pau CP, Hendry RM, Otten R, McNicholl J, Buckheit R Jr, Smith J, Kiser PF, Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2012 Mar;56(3):1291-9
Kiser PF, Johnson TJ, Clark JT, State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev 2012 Jan-Mar;14(1):62-77
Clark MR, Johnson TJ, McCabe RT, Clark JT, Tuitupou A, Elgendy H, Friend DR, Kiser PF, A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci 2012 Feb;101(2):576-87
Mahalingam A, Geonnotti AR, Balzarini J, Kiser PF, Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharm 2011 Dec 5;8(6):2465-75
Mahalingam A, Jay JI, Langheinrich K, Shukair S, McRaven MD, Rohan LC, Herold BC, Hope TJ, Kiser PF, Inhibition of the transport of HIV in vitro using a pH-responsive synthetic mucin-like polymer system. Biomaterials 2011 Nov;32(33):8343-55
Clark MR, Aliyar HA, Lee CW, Jay JI, Gupta KM, Watson KM, Stewart RJ, Buckheit RW, Kiser PF, Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles. Int J Pharm 2011 Jul 15;413(1-2):10-18
Mahalingam A, Simmons AP, Ugaonkar SR, Watson KM, Dezzutti CS, Rohan LC, Buckheit RW Jr, Kiser PF, Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother 2011 Apr;55(4):1650-60
Mahalingam A, Smith E, Fabian J, Damian FR, Peters JJ, Clark MR, Friend DR, Katz DF, Kiser PF, Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res 2010 Nov;27(11):2478-91
Damian F, Fabian J, Friend DR, Kiser PF, Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions. Int J Pharm 2010 Aug 30;396(1-2):1-10
Jay JI, Lai BE, Myszka DG, Mahalingam A, Langheinrich K, Katz DF, Kiser PF, Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors. Mol Pharm 2010 Feb 1;7(1):116-29
Johnson TJ, Gupta KM, Fabian J, Albright TH, Kiser PF, Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 2010 Feb 19;39(4):203-12
Jay JI, Shukair S, Langheinrich K, Hanson MC, Cianci GC, Johnson TJ, Clark MR, Hope TJ, Kiser PF, Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater 2009 Sep 23;19(18):2969-2977
Roberts MC, Mahalingam A, Hanson MC, Kiser PF, Chemorheology of phenylboronate-salicylhydroxamate crosslinked hydrogel networks with a sulfonated polymer backbone. Macromolecules 2008 Nov 25;41(22):8832-8840
Gupta KM, Pearce SM, Poursaid AE, Aliyar HA, Tresco PA, Mitchnik MA, Kiser PF, Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci 2008 Oct;97(10):4228-39
Gupta KM, Barnes SR, Tangaro RA, Roberts MC, Owen DH, Katz DF, Kiser PF, Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J Pharm Sci 2007 Mar;96(3):670-81
Endrizzi BJ, Huang G, Kiser PF, Stewart RJ, Specific covalent immobilization of proteins through dityrosine cross-links. Langmuir 2006 Dec 19;22(26):11305-10
Stayner RS, Min DJ, Kiser PF, Stewart RJ, Site-specific cross-linking of proteins through tyrosine hexahistidine tags. Bioconjug Chem 2005 Nov-Dec;16(6):1617-23
Oortgiesen M, Veronesi B, Eichenbaum G, Kiser PF, Simon S , Residual oil fly ash and charged polymers activate epithelial cells and nociceptive sensory neurons. Am J Physiol Lung Cell Mol Physiol 2000 Apr;278(4):L683-95
Eichenbaum GM, Kiser PF, Simon SA, Needham , pH and Ion-Triggered Volume Response of Anionic Hydrogel Microspheres. Macromolecules 1998 Jul 28;31(15):5084-93
Kiser PF, Wilson G, Needham , A synthetic mimic of the secretory granule for drug delivery. Nature 1998 Jul 30;394(6692):459-62